Claims
- 1. Compounds of Formula I:
- 2. Compounds of Formula II:
- 3. Compounds of Formula III:
- 4. The compound of claim 1, which is 6-Methoxy-5-({[4-(trifluoromethoxy)benzyl]amino}methyl)-2-naphthoic acid.
- 5. The compound of claim 1, which is 5-{[(4-Fluorobenzyl)amino]methyl)-6-methoxy-2-naphthoic acid.
- 6. The compound of claim 1, which is 5-({[4-(Aminosulfonyl)benzyl]amino}methyl)-6-methoxy-2-naphthoic acid.
- 7. The compound of claim 1, which is 5-({[4-(Dimethylamino)benzyl]amino}methyl)-6-methoxy-2-naphthoic acid.
- 8. The compound of claim 1, which is 6-(Carboxymethoxy)-5-({[4-(trifluoromethoxy)benzyl]amino}methyl)-2-naphthoic acid.
- 9. A method of treating metabolic disorders mediated by insulin resistance or hyperglycemia in a mammal in need thereof which comprises administering to said mammal, a therapeutically effective amount of a compound of Formula I:
- 10. A method of treating or inhibiting type II diabetes in a mammal in need thereof which comprises administering to said mammal a therapeutically effective amount of compound of Formula I:
- 11. A method of modulating glucose levels in a mammal in need thereof which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I:
- 12. A pharmaceutical composition which comprises a compound of Formula I:
Parent Case Info
[0001] This application claims priority from co-pending provisional application serial No. 60/408,314 filed on Sep. 5, 2002 the entire disclosure of which is hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60408314 |
Sep 2002 |
US |